US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
美国食品药品监督管理局批准摘要:Elacestrant 用于治疗雌激素受体阳性、人表皮生长因子受体 2 阴性、ESR1 突变的晚期或转移性乳腺癌
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.23.02112
Shah, Mirat; Lingam, Hima; Gao, Xin; Gittleman, Haley; Fiero, Mallorie H; Krol, Danielle; Biel, Nikolett; Ricks, Tiffany K; Fu, Wentao; Hamed, Salaheldin; Li, Fang; Sun, Jillian Jielin; Fan, Jianghong; Schuck, Robert; Grimstein, Manuela; Tang, Liuya; Kalavar, Shyam; Abukhdeir, Abdelrahmman; Pathak, Anand; Ghosh, Soma; Bulatao, Ilynn; Tilley, Amy; Pierce, William F; Mixter, Bronwyn D; Tang, Shenghui; Pazdur, Richard; Kluetz, Paul; Amiri-Kordestani, Laleh